GLP-1 & Incretin Science

SELECT: The Trial That Changed What the Class Was For

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

SELECT enrolled 17,604 participants with overweight or obesity and established cardiovascular disease but without diabetes, testing semaglutide against placebo on major adverse cardiovascular events. Lincoff and colleagues published it in the New England Journal of Medicine in December 2023.

Key facts

Enrolment
17,604
Population
Obesity + established CV disease, no diabetes
Endpoint
Major adverse cardiovascular events
Published
NEJM 2023 (PMID 37952131)
Weight analysis
Ryan 2024, Nat Med (PMID 38740993)
Significance
Outcome benefit outside diabetes

Why excluding diabetes was the whole design

Cardiovascular outcome trials of diabetes drugs had already shown benefit, but in people with diabetes any cardiovascular effect could plausibly be explained by better glucose control. Removing diabetes from the population removes that explanation. Whatever SELECT found could not be attributed to glycaemic improvement, because the participants were not hyperglycaemic to begin with.

Why the size was necessary

Counting heart attacks, strokes and cardiovascular deaths requires enough events to distinguish a real difference from noise, and those events are relatively rare even in a high-risk population. 17,604 participants followed for years is what it takes. That scale is why outcome trials cost what they do and why most compounds never get one.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What it established for the category

That the benefit extends beyond glucose and beyond weight as a number. A drug demonstrating reduced cardiovascular events in people without diabetes is being assessed as a cardiovascular agent, which is a different regulatory and clinical proposition from a weight-management product.

The question it left open

How much of the effect ran through weight reduction and how much through other mechanisms. Ryan and colleagues examined the long-term weight outcomes in SELECT separately in Nature Medicine in 2024. Weight and cardiovascular benefit travel together in the same participants, so attribution remains difficult.

Why it sits beside FLOW and ESSENCE

Three large trials, three organ systems, one compound: cardiovascular events in SELECT, kidney events in FLOW, liver histology in ESSENCE. Read together they describe a metabolic agent rather than an appetite suppressant, and that reframing is the most consequential thing to have happened to this drug class since the weight results themselves.

And what it says about research material

Nothing. SELECT studied a licensed medicine in 17,604 patients under clinical supervision with ethics approval and event adjudication. No research compound is covered by those findings or is an alternative to a prescribed cardiovascular treatment.

Quick reference

TrialOrgan systemEnrolmentEndpoint type
SELECTCardiovascular17,604Clinical events
FLOWKidney3,533Clinical events
ESSENCELiver1,205Histological surrogate

Frequently asked questions

Why did SELECT exclude people with diabetes?

So any cardiovascular benefit could not be attributed to improved glucose control. The participants were not hyperglycaemic to begin with.

Why did it need 17,604 participants?

Cardiovascular events are relatively rare even in high-risk populations, and detecting a real difference requires enough of them.

Was the benefit caused by weight loss?

Not separable. Weight reduction and cardiovascular benefit occurred in the same participants, so attribution remains difficult.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.